BioTime, Inc. to Provide Company Updates During Investor Day, October 28, 2013
ALAMEDA, Calif.--(BUSINESS WIRE)--Oct. 28, 2013--
BioTime, Inc. (NYSE MKT: BTX) announced today that it will be holding
its annual Investor Day providing company updates at the Harvard Club in
New York City. The presentations will be available on the company
Thomas Okarma, M.D., Ph.D., President and CEO of Asterias
Biotherapeutics Inc., will present a summary of Asterias, a new
subsidiary of BioTime. Asterias recently acquired Geron Corporation’s
human embryonic stem cell assets, as well as certain assets from
BioTime, including rights to use certain human embryonic stem cell lines
developed by BioTime’s subsidiary ES Cell International Pte Ltd.,
minority stakes in two of BioTime’s other subsidiaries, and BioTime
William Tew, Ph.D., BioTime’s Chief Commercial Officer will provide an
update on the development of Renevia™. In his presentation, Dr.
Tew will announce that enrollment in a safety trial evaluating Renevia™,
a proprietary injectable matrix designed to facilitate the stable
engraftment of transplanted cells, is complete and the initial ten
subjects who each received one subcutaneous injection of Renevia™
have been followed for three weeks after treatment and to date, Renevia™
has been well-tolerated by all patients with no serious adverse events.
BioTime will also describe new work using BioTime’s HyStem®
technology to develop 3D cell culture platforms for improved methods of
screening new anti-cancer drug candidates in a project funded by a
research grant from the National Institutes of Health.
Charles S. Irving, Ph.D., the CEO of BioTime’s subsidiary Cell Cure
Neurosciences Ltd. will provide an update on the development of OpRegen®.
In his presentation, Dr. Irving will describe the unmet medical needs
and markets for the treatment of the dry form of age-related macular
degeneration (AMD), and the advantages of Cell Cure’s OpRegen®
which has been produced from human embryonic stem cells in culture
conditions free of animal products, eliminating the need for designating
the product as a xenotransplantation therapeutic. Dr. Irving’s
presentation will contain assessments of Cell Cure’s approach by key
opinion leaders in the fields of macular degeneration and human
embryonic stem cell research. Dr. Irving will describe the progress of
the ongoing preclinical studies which are expected to lead to regulatory
filings for the initiation of human clinical trials in 2014.
Joe Wagner, Ph.D., the CEO of BioTime’s subsidiary OncoCyte Corporation
will provide an update on development of the Company’s PanC-Dx™ family
of cancer diagnostic products. Dr. Wagner will describe genomic and
proteomic technology developed at OncoCyte that forms the basis of these
products. His talk will include information on plans for clinical trials
of PanC-Dx™ in breast cancer and bladder cancer screening and new
planned clinical trial in mammography patients and the recently
announced lung cancer study being conducted with The Wistar Institute.
David Warshawsky, the CEO of BioTime’s subsidiary LifeMap Sciences,
Inc., will provide an update on LifeMap’s business. He will report on
the Integrated Biomedical Knowledgebase and discovery platform for
biomedical research, including GeneCards®, LifeMap Discovery™
Francois Binette, Ph.D., the Vice President of Research and Business
Development of BioTime’s subsidiary OrthoCyte Corporation, will describe
the discovery effort at OrthoCyte focusing on the development of novel
regenerative therapeutics for various orthopedic diseases and injuries.
Dr. Binette will also describe some of the promising results obtained
with the collaboration of University of California San Diego Prof.
Koichi Masuda M.D., Director of Skeletal Translational Research
Laboratory, Department of Orthopaedic Surgery, School of Medicine, using
progenitor OTX-05,-07,-09 in an ex vivo model for degenerative disc
disease, the principal cause of chronic back pain. Chronic back pain is
one of the largest health economics burden in modern societies since
there are no treatment or cure for a condition that affects more than
85% of the population in their lifetime.
David Larocca, Ph.D., the recently appointed vice president of research
and development of BioTime’s subsidiary ReCyte Therapeutics, Inc., will
provide an update on the development of vascular progenitor cells for
the treatment of heart disease.
About BioTime, Inc.
BioTime is a biotechnology company engaged in research and product
development in the field of regenerative medicine. Regenerative medicine
refers to therapies based on stem cell technology that are designed to
rebuild cell and tissue function lost due to degenerative disease or
injury. BioTime’s focus is on pluripotent stem cell technology based on
human embryonic stem (“hES”) cells and induced pluripotent stem (“iPS”)
cells. hES and iPS cells provide a means of manufacturing every cell
type in the human body and therefore show considerable promise for the
development of a number of new therapeutic products. BioTime’s
therapeutic and research products include a wide array of proprietary PureStem™
progenitors, HyStem® hydrogels, culture media, and
differentiation kits. BioTime is developing Renevia™ (a HyStem®
product) as a biocompatible, implantable hyaluronan and collagen-based
matrix for cell delivery in human clinical applications. In addition,
BioTime has developed Hextend®, a blood
plasma volume expander for use in surgery, emergency trauma treatment
and other applications. Hextend® is manufactured and
distributed in the U.S. by Hospira, Inc. and in South Korea by CJ
CheilJedang Corporation under exclusive licensing agreements.
BioTime is also developing stem cell and other products for research,
therapeutic, and diagnostic use through its subsidiaries:
OncoCyte Corporation is developing products and technologies to
diagnose and treat cancer.
ES Cell International Pte Ltd., a Singapore private limited company,
develops hES products for research use.
BioTime Asia, Limited, a Hong Kong company, may offer and sell
products for research use for BioTime’s ESI BIO Division.
OrthoCyte Corporation is developing therapies to treat orthopedic
disorders, diseases and injuries.
ReCyte Therapeutics, Inc. is developing therapies to treat a variety
of blood and lymphatic vascular disorders, as well as products for
research using iPS and other cell reprogramming technology.
Cell Cure Neurosciences Ltd. is an Israel-based biotechnology company
focused on developing stem cell-based therapies for retinal and
neurological degenerative diseases. Its lead product is OpRegen®
for the treatment of macular degeneration.
LifeMap Sciences, Inc. markets, sells and distributes GeneCards®,
the leading human gene database, as part of an integrated database
suite that also includes the LifeMap Discovery™ database of
embryonic development, stem cell research and regenerative medicine,
and MalaCards, the human disease database.
Asterias Biotherapeutics, Inc. is a new subsidiary that recently
acquired the stem cell assets of Geron Corporation, including patents
and other intellectual property, biological materials, reagents and
equipment for the development of new therapeutic products for
Additional information about BioTime can be found on the web at www.biotimeinc.com.
Statements pertaining to future financial and/or operating results,
future growth in research, technology, clinical development, and
potential opportunities for BioTime and its subsidiaries, along with
other statements about the future expectations, beliefs, goals, plans,
or prospects expressed by management constitute forward-looking
statements. Any statements that are not historical fact (including, but
not limited to statements that contain words such as "will," "believes,"
"plans," "anticipates," "expects," "estimates") should also be
considered to be forward-looking statements. Forward-looking statements
involve risks and uncertainties, including, without limitation, risks
inherent in the development and/or commercialization of potential
products, uncertainty in the results of clinical trials or regulatory
approvals, need and ability to obtain future capital, and maintenance of
intellectual property rights. Actual results may differ materially from
the results anticipated in these forward-looking statements and as such
should be evaluated together with the many uncertainties that affect the
business of BioTime and its subsidiaries, particularly those mentioned
in the cautionary statements found in BioTime's Securities and Exchange
Commission filings. BioTime disclaims any intent or obligation to update
these forward-looking statements.
To receive ongoing BioTime corporate communications, please click on the
following link to join our email alert list: http://news.biotimeinc.com
Source: BioTime, Inc.
Lesley Stolz, PhD
Executive Vice President,
510-521-3390, ext 367
510-521-3390, ext 301